Drugs.com - Clinical Trials

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent...

Mar 15, 2025 - 00:11
 0
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent...
Read More

Tags:

Previous Article

How nGroup & Locus Robotics Boosted Warehouse Productivity by 229%

Next Article

5 Acre Estate In Gastonia, North Carolina (PHOTOS)

Related Posts

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial of Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Tris Pharma Announces Positive Results from ALLEVIATE-1...

Feb 9, 2025  0

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BioRestorative Receives FDA Fast Track Designation for ...

Mar 1, 2025  0

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

Arvinas and Pfizer Announce Positive Topline Results fr...

Mar 12, 2025  0